immuno-oncology

News

ASCO: AffyImmune claims a first with CAR-T for solid tumours

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy.

News

FDA clears BMS’ Breyanzi for follicular lymphoma

Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

News

Dr Elias Sayour, Chong Zhao and Arnav Barpujari discuss the mRNA cancer vaccine developed at the University of Florida

RNA glioblastoma vaccine shows promise in first human trial

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial.

News

EU OK sets up first ex-China launches for BeiGene's Tevimbra

BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside

News

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.

ASCO: AffyImmune claims a first with CAR-T for solid tumours

FDA clears BMS’ Breyanzi for follicular lymphoma

MSD has another TIGIT programme setback

RNA glioblastoma vaccine shows promise in first human trial

EU OK sets up first ex-China launches for BeiGene's Tevimbra

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

Novo Nordisk fight with KBP Bio will go to arbitration

Discover a new era of healthcare panel engagement: Grounded ...

immuno-oncology

Editor's Picks